Walleye Capital’s Denali Therapeutics DNLI Stock Holding History

Walleye Capital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,500	Closed	-$32.2K	–	5501
2023 Q4	$32.2K	Buy	+1,500	New	+$29.7K	﹤0.01%	4393

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital's DNLI Position: Q1 2026 in Review

Walleye Capital sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 12,652 shares — an estimated $209K sold.

Walleye Capital first reported a position in DNLI in Q4 2020 and held it in 6 quarters. The position peaked at $910K in Q1 2022. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Walleye Capital reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 12,652 Denali Therapeutics shares in Q1 2026, an estimated $209K.
Walleye Capital first reported a position in Denali Therapeutics in Q4 2020 and held it in 6 quarters.
Walleye Capital's Denali Therapeutics position peaked at $910K in Q1 2022.
268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.